Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Management of adjuvant/neoadjuvant HCC in 2024 

How to select first-line and what to do after progression to immunotherapy

Date

16 Sep 2024

Session

Management of adjuvant/neoadjuvant HCC in 2024 

Topics

Immunotherapy

Tumour Site

Hepatobiliary Cancers

Presenters

Lorenza Rimassa

Authors

L. Rimassa

Author affiliations

  • Humanitas Cancer Center, IRCCS Humanitas Research Hospital, 20089 - Rozzano/IT

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Presentation of case/condition

Presenter: Anna Saborowski

Session: Management of adjuvant/neoadjuvant HCC in 2024 

Resources:

Slides

Webcast

Update on adjuvant treatment

Presenter: Tim Meyer

Session: Management of adjuvant/neoadjuvant HCC in 2024 

Resources:

Slides

Webcast

Discussion

Session: Management of adjuvant/neoadjuvant HCC in 2024 

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.